html5-img
1 / 34

Management of Relapsed / Refractory RCC

Management of Relapsed / Refractory RCC. Sequential Therapy?. Sequencing Targeted Agents in RCC. Targeted Agents: Vertical Inhibition . Targeted Agents: Horizontal Inhibition . Relative Affinities of VEGFR TKIs. TKIs After Immunotherapy: Activity of Sorafenib.

juliet
Télécharger la présentation

Management of Relapsed / Refractory RCC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of Relapsed / Refractory RCC

  2. Sequential Therapy?

  3. Sequencing Targeted Agents in RCC

  4. Targeted Agents: Vertical Inhibition

  5. Targeted Agents: Horizontal Inhibition

  6. Relative Affinities of VEGFR TKIs

  7. TKIs After Immunotherapy: Activity of Sorafenib

  8. Several Drugs are Active After Cytokines

  9. Data Supporting Use of Sequential Therapy

  10. Patients With Prior Anti-Angiogenic Tx Achieve Additional Benefit With Sorafenib

  11. Sequential Therapy: Should Second-line Therapy be a Consideration When Selecting First-line Therapy?

  12. Sequential Therapy: Should Second-line Therapy be a Consideration When Selecting First-line Therapy?

  13. Renal Cell Cancer Oral RAD 001 given Daily RECORD -1 Trial Design (n = 416)

  14. Progression-Free Survival by Treatment Central Radiology Review

  15. Overall Survival

  16. Ongoing Clinical Trials in RCC:Sequential Therapies

  17. SWITCH Study to Identify the Best Sequence (N = 540)

  18. RECORD - 3: Phase II Sequence Trial of Everolimus and Sunitinib

  19. Development of Resistance: Angiogenic Escape

  20. Sequential Therapy in RCC

More Related